Mesenchymal stem cells: Immunomodulatory capability and clinical potential in immune diseases

Journal of Cellular Immunotherapy

Volumn 2, Issue 1, 2016, Pages 3-20

  Zhao, Qinjun ^a   Ren, Hongying ^b   Han, Zhongchao ^a,b  

^a National Engineering Research Center of Cell Products   (China)

^b INSTITUTE OF HEMATOLOGY AND BLOOD DISEASES HOSPITAL   (China)

Author keywords

Biological effectiveness; Cell infusion; Immunomodulatory; MSCs

Indexed keywords

ACUTE GRAFT VERSUS HOST DISEASE; ADAPTIVE IMMUNITY; ANTIBODY PRODUCTION; APLASTIC ANEMIA; B LYMPHOCYTE; CELL DIFFERENTIATION; CELL INTERACTION; CELL MATURATION; CELL VIABILITY; CHRONIC GRAFT VERSUS HOST DISEASE; CROHN DISEASE; CYTOTOXICITY; DENDRITIC CELL; HUMAN; HUMORAL IMMUNITY; IMMUNOMODULATION; IMMUNOPATHOLOGY; IMMUNOSUPPRESSIVE TREATMENT; IN VIVO STUDY; INFLAMMATORY DISEASE; INNATE IMMUNITY; LYMPHOCYTE PROLIFERATION; MACROPHAGE; MALIGNANT TRANSFORMATION; MESENCHYMAL STEM CELL TRANSPLANTATION; MONOCYTE; NATURAL KILLER T CELL; NEUTROPHIL; NONHUMAN; PHENOTYPE; RANDOMIZED CONTROLLED TRIAL (TOPIC); REGULATORY T LYMPHOCYTE; REVIEW; RHEUMATOID ARTHRITIS; SYSTEMIC LUPUS ERYTHEMATOSUS; T LYMPHOCYTE;

EID: 85038124867     PISSN: None     EISSN: 23521775     Source Type: Journal    
DOI: 10.1016/j.jocit.2014.12.001     Document Type: Review

References (190)

1. Friedenstein A.J., Piatetzky S., Petrakova K.V. Osteogenesis in transplants of bone marrow cells. J Embryol Exp Morphol 1966, 16(3):381-390.
2. Friedenstein A.J., Chailakhyan R.K., Latsinik N.V., Panasyuk A.F., Keiliss-Borok I.V. Stromal cells responsible for transferring the microenvironment of the hemopoietic tissues. Cloning in vitro and retransplantation in vivo. Transplantation 1974, 17(4):331-340.
3. Zuk P.A., Zhu M., Ashjian P., De Ugarte D.A., Huang J.I., Mizuno H., et al. Human adipose tissue is a source of multipotent stem cells. Mol Biol Cell 2002, 13(12):4279-4295.
4. Zhang H.J., Miao Z.C., He Z.P., Yang Y.X., Wang Y., Feng M.F. The existence of epithelial-to-mesenchymal cells with the ability to support hematopoiesis in human fetal liver. Cell Biol Int 2005, 29(3):213-219.
5. Tondreau T., Meuleman N., Delforge A., Dejeneffe M., Leroy R., Massy M., et al. Mesenchymal stem cells derived from CD133-positive cells in mobilized peripheral blood and cord blood: proliferation, Oct4 expression, and plasticity. Stem cells 2005, 23(8):1105-1112.
6. Zheng C.L., Yang S.G., Guo Z.X., Dong C.L., Liang L., Chen X.J., et al. Human Multipotent mesenchymal stromal cells from fetal lung expressing pluripotent markers and differentiating into cell types of three germ layers. Cell Transplant 2009, 18(10):1093-1109.
7. Fukuchi Y., Nakajima H., Sugiyama D., Hirose I., Kitamura T., Tsuji K. Human placenta-derived cells have mesenchymal stem/progenitor cell potential. Stem cells 2004, 22(5):649-658.
8. Sarugaser R., Lickorish D., Baksh D., Hosseini M.M., Davies J.E. Human umbilical cord perivascular (HUCPV) cells: a source of mesenchymal progenitors. Stem Cells 2005, 23(2):220-229.
9. Lu L.L., Liu Y.J., Yang S.G., Zhao Q.J., Wang X., Gong W., et al. Isolation and characterization of human umbilical cord mesenchymal stem cells with hematopoiesis-supportive function and other potentials. Haematologica 2006, 91(8):1017-1026.
10. Huang G.T., Gronthos S., Shi S. Mesenchymal stem cells derived from dental tissues vs. those from other sources: their biology and role in regenerative medicine. J Dent Res 2009, 88(9):792-806.
11. Hermida-Gomez T., Fuentes-Boquete I., Gimeno-Longas M.J., Muinos-Lopez E., Diaz-Prado S., de Toro F.J., et al. Quantification of cells expressing mesenchymal stem cell markers in healthy and osteoarthritic synovial membranes. J Rheumatol 2011, 38(2):339-349.
12. Park J.C., Kim J.M., Jung I.H., Kim J.C., Choi S.H., Cho K.S., et al. Isolation and characterization of human periodontal ligament (PDL) stem cells (PDLSCs) from the inflamed PDL tissue: in vitro and in vivo evaluations. J Clin Periodontol 2011, 38(8):721-731.
13. Schwab K.E., Hutchinson P., Gargett C.E. Identification of surface markers for prospective isolation of human endometrial stromal colony-forming cells. Human Reprod 2008, 23(4):934-943.
14. Sakaguchi Y., Sekiya I., Yagishita K., Ichinose S., Shinomiya K., Muneta T. Suspended cells from trabecular bone by collagenase digestion become virtually identical to mesenchymal stem cells obtained from marrow aspirates. Blood 2004, 104(9):2728-2735.
15. Zhu H., Guo Z.K., Jiang X.X., Li H., Wang X.Y., Yao H.Y., et al. A protocol for isolation and culture of mesenchymal stem cells from mouse compact bone. Nat Protoc 2010, 5(3):550-560.
16. Wang Y., Han Z.B., Ma J., Zuo C., Geng J., Gong W., et al. A toxicity study of multiple-administration human umbilical cord mesenchymal stem cells in cynomolgus monkeys. Stem Cells Dev 2012, 21(9):1401-1408.
17. Wang Y., Zhang Z., Chi Y., Zhang Q., Xu F., Yang Z., et al. Long-term cultured mesenchymal stem cells frequently develop genomic mutations but do not undergo malignant transformation. Cell Death Dis 2013, 4. e950.
18. Pittenger M.F., Mackay A.M., Beck S.C., Jaiswal R.K., Douglas R., Mosca J.D., et al. Multilineage potential of adult human mesenchymal stem cells. Science 1999, 284(5411):143-147.
19. Simmons P.J., Torok-Storb B. Identification of stromal cell precursors in human bone marrow by a novel monoclonal antibody, STRO-1. Blood 1991, 78(1):55-62.
20. Barry F.P., Boynton R.E., Haynesworth S., Murphy J.M., Zaia J. The monoclonal antibody SH-2, raised against human mesenchymal stem cells, recognizes an epitope on endoglin (CD105). Biochem Biophys Res Commun 1999, 265(1):134-139.
21. Barry F., Boynton R., Murphy M., Haynesworth S., Zaia J. The SH-3 and SH-4 antibodies recognize distinct epitopes on CD73 from human mesenchymal stem cells. Biochem Biophys Res Commun 2001, 289(2):519-524.
22. Martinez C., Hofmann T.J., Marino R., Dominici M., Horwitz E.M. Human bone marrow mesenchymal stromal cells express the neural ganglioside GD2: a novel surface marker for the identification of MSCs. Blood 2007, 109(10):4245-4248.
23. Xu J., Liao W.B., Gu D.S., Liang L., Du W.T., Liu P.X., et al. Neural ganglioside GD2 identifies a subpopulation of MSC in human umbilical cord. Cell Physiol Biochem 2009, 23(4-6):415-424.
24. Majumdar M.K., Keane-Moore M., Buyaner D., Hardy W.B., Moorman M.A., McIntosh K.R., et al. Characterization and functionality of cell surface molecules on human mesenchymal stem cells. J Biomedical Sci 2003, 10(2):228-241.
25. Majumdar M.K., Thiede M.A., Mosca J.D., Moorman M., Gerson S.L. Phenotypic and functional comparison of cultures of marrow-derived mesenchymal stem cells (MSCs) and stromal cells. J Cell Physiol 1998, 176(1):57-66.
26. Le Blanc K., Tammik C., Rosendahl K., Zetterberg E., Ringden O. HLA expression and immunologic properties of differentiated and undifferentiated mesenchymal stem cells. Exp Hematol 2003, 31(10):890-896.
27. Zhao Q., Ren H., Li X., Chen Z., Zhang X., Gong W., et al. Differentiation of human umbilical cord mesenchymal stromal cells into low immunogenic hepatocyte-like cells. Cytotherapy 2009, 11(4):414-426.
28. Klyushnenkova E., Mosca J.D., Zernetkina V., Majumdar M.K., Beggs K.J., Simonetti D.W., et al. T cell responses to allogeneic human mesenchymal stem cells: immunogenicity, tolerance, and suppression. J Biomed Sci 2005, 12(1):47-57.
29. Weiss M.L., Anderson C., Medicetty S., Seshareddy K.B., Weiss R.J., Vander-Werff I., et al. Immune properties of human umbilical cord Wharton's jelly-derived cells. Stem cells 2008, 26(11):2865-2874.
30. Dominici M., Le Blanc K., Mueller I., Slaper-Cortenbach I., Marini F., Krause D., et al. Minimal criteria for defining multipotent mesenchymal stromal cells. The International Society for Cellular Therapy position statement. Cytotherapy 2006, 8(4):315-317.
31. Wislet-Gendebien S., Hans G., Leprince P., Rigo J.M., Moonen G., Rogister B. Plasticity of cultured mesenchymal stem cells: switch from nestin-positive to excitable neuron-like phenotype. Stem Cells 2005, 23(3):392-402.
32. Battula V.L., Treml S., Bareiss P.M., Gieseke F., Roelofs H., de Zwart P., et al. Isolation of functionally distinct mesenchymal stem cell subsets using antibodies against CD56, CD271, and mesenchymal stem cell antigen-1. Haematologica 2009, 94(2):173-184.
33. Yang Z.X., Han Z.B., Ji Y.R., Wang Y.W., Liang L., Chi Y., et al. CD106 identifies a subpopulation of mesenchymal stem cells with unique immunomodulatory properties. PLoS One 2013, 8(3). e59354.
34. Bruder S.P., Kurth A.A., Shea M., Hayes W.C., Jaiswal N., Kadiyala S. Bone regeneration by implantation of purified, culture-expanded human mesenchymal stem cells. J Orthop Res 1998, 16(2):155-162.
35. Noel D., Gazit D., Bouquet C., Apparailly F., Bony C., Plence P., et al. Short-term BMP-2 expression is sufficient for in vivo osteochondral differentiation of mesenchymal stem cells. Stem Cells 2004, 22(1):74-85.
36. Gross-Aviv T., Vago R. The role of aragonite matrix surface chemistry on the chondrogenic differentiation of mesenchymal stem cells. Biomaterials 2009, 30(5):770-779.
37. Lee H.K., Lee B.H., Park S.A., Kim C.W. The proteomic analysis of an adipocyte differentiated from human mesenchymal stem cells using two-dimensional gel electrophoresis. Proteomics 2006, 6(4):1223-1229.
38. Wall M.E., Bernacki S.H., Loboa E.G. Effects of serial passaging on the adipogenic and osteogenic differentiation potential of adipose-derived human mesenchymal stem cells. Tissue Eng 2007, 13(6):1291-1298.
39. Krampera M., Pizzolo G., Aprili G., Franchini M. Mesenchymal stem cells for bone, cartilage, tendon and skeletal muscle repair. Bone 2006, 39(4):678-683.
40. Noack S., Seiffart V., Willbold E., Laggies S., Winkel A., Shahab-Osterloh S., et al. Periostin secreted by mesenchymal stem cells supports tendon formation in an ectopic mouse model. Stem Cells Dev 2014, 23(16):1844-1857.
41. Dodin G., Andrieux M., al Kabbani H. Binding of ellipticine to beta-lactoglobulin. A physico-chemical study of the specific interaction of an antitumor drug with a transport protein. Eur J Biochem 1990, 193(3):697-700.
42. Labovsky V., Hofer E.L., Feldman L., Fernandez Vallone V., Garcia Rivello H., Bayes-Genis A., et al. Cardiomyogenic differentiation of human bone marrow mesenchymal cells: Role of cardiac extract from neonatal rat cardiomyocytes. Differentiation 2010, 79(2):93-101.
43. Wang J.F., Wang L.J., Wu Y.F., Xiang Y., Xie C.G., Jia B.B., et al. Mesenchymal stem/progenitor cells in human umbilical cord blood as support for ex vivo expansion of CD34(+) hematopoietic stem cells and for chondrogenic differentiation. Haematologica 2004, 89(7):837-844.
44. Zhou S.B., Wang J., Chiang C.A., Sheng L.L., Li Q.F. Mechanical stretch upregulates SDF-1alpha in skin tissue and induces migration of circulating bone marrow-derived stem cells into the expanded skin. Stem Cells 2013, 31(12):2703-2713.
45. Padovan C.S., Jahn K., Birnbaum T., Reich P., Sostak P., Strupp M., et al. Expression of neuronal markers in differentiated marrow stromal cells and CD133+ stem-like cells. Cell Transplant 2003, 12(8):839-848.
46. Kotton D.N., Ma B.Y., Cardoso W.V., Sanderson E.A., Summer R.S., Williams M.C., et al. Bone marrow-derived cells as progenitors of lung alveolar epithelium. Development 2001, 128(24):5181-5188.
47. Li Y., Xu W., Yan J., Xia Y., Gu C., Ma Y., et al. Differentiation of human amniotic fluid-derived mesenchymal stem cells into type II alveolar epithelial cells in vitro. Int J Mol Med 2014, 33(6):1507-1513.
48. Chien C.C., Yen B.L., Lee F.K., Lai T.H., Chen Y.C., Chan S.H., et al. In vitro differentiation of human placenta-derived multipotent cells into hepatocyte-like cells. Stem Cells 2006, 24(7):1759-1768.
49. Sam R. The role of epithelial to mesenchymal transdifferentiation in end-stage renal disease. Int J Artif Organs 2004, 27(9):744-750.
50. Singaravelu K., Padanilam B.J. In vitro differentiation of MSC into cells with a renal tubular epithelial-like phenotype. Ren Fail 2009, 31(6):492-502.
51. Karaoz E., Okcu A., Unal Z.S., Subasi C., Saglam O., Duruksu G. Adipose tissue-derived mesenchymal stromal cells efficiently differentiate into insulin-producing cells in pancreatic islet microenvironment both in vitro and in vivo. Cytotherapy 2013, 15(5):557-570.
52. Moriscot C., de Fraipont F., Richard M.J., Marchand M., Savatier P., Bosco D., et al. Human bone marrow mesenchymal stem cells can express insulin and key transcription factors of the endocrine pancreas developmental pathway upon genetic and/or microenvironmental manipulation in vitro. Stem Cells 2005, 23(4):594-603.
53. Alviano F., Fossati V., Marchionni C., Arpinati M., Bonsi L., Franchina M., et al. Term Amniotic membrane is a high throughput source for multipotent Mesenchymal Stem Cells with the ability to differentiate into endothelial cells in vitro. BMC Dev Biol 2007, 7:11.
54. Bell E., Richardson G.D., Jahoda C.A., Gledhill K., Phillips H.M., Henderson D., et al. Dermal stem cells can differentiate down an endothelial lineage. Stem Cells Dev 2012, 21(16):3019-3030.
55. Bernardo M.E., Zaffaroni N., Novara F., Cometa A.M., Avanzini M.A., Moretta A., et al. Human bone marrow derived mesenchymal stem cells do not undergo transformation after long-term in vitro culture and do not exhibit telomere maintenance mechanisms. Cancer Res 2007, 67(19):9142-9149.
56. Meza-Zepeda L.A., Noer A., Dahl J.A., Micci F., Myklebost O., Collas P. High-resolution analysis of genetic stability of human adipose tissue stem cells cultured to senescence. J Cell Mol Med 2008, 12(2):553-563.
57. Poloni A., Maurizi G., Babini L., Serrani F., Berardinelli E., Mancini S., et al. Human mesenchymal stem cells from chorionic villi and amniotic fluid are not susceptible to transformation after extensive in vitro expansion. Cell Transplant 2011, 20(5):643-654.
58. Chen G., Yue A., Ruan Z., Yin Y., Wang R.Z., Ren Y., et al. Human umbilical cord-derived mesenchymal stem cells do not undergo malignant transformation during long-term culturing in serum-free medium. PLoS One 2014, 9(6). e98565.
59. Feng M., Li Y., Han Q., Bao X., Yang M., Zhu H., et al. Preclinical safety evaluation of human mesenchymal stem cell transplantation in cerebrum of nonhuman primates. Int J Toxicol 2014, 33(5):403-411.
60. Francois S., Usunier B., Douay L., Benderitter M., Chapel A. Long-term quantitative biodistribution and side effects of human mesenchymal stem cells (hMSCs) engraftment in NOD/SCID mice following irradiation. Stem Cells Int 2014, 2014:939275.
61. Shi M., Zhang Z., Xu R., Lin H., Fu J., Zou Z., et al. Human mesenchymal stem cell transfusion is safe and improves liver function in acute-on-chronic liver failure patients. Stem Cells Transl Med 2012, 1(10):725-731.
62. Wang L.M., Wang L.H., Cong X.L., Liu G.Y., Zhou J.J., Bai B., et al. Human umbilical cord mesenchymal stem cell therapy for patients with active rheumatoid arthritis: safety and efficacy. Stem Cells Dev 2013, 22(24):3192-3202.
63. Rodrigo S.F., van Ramshorst J., Hoogslag G.E., Boden H., Velders M.A., Cannegieter S.C., et al. Intramyocardial injection of autologous bone marrowderived ex vivo expanded mesenchymal stem cells in acute myocardial infarction patients is feasible and safe up to 5 years of follow-up. J Cardiovasc Transl Res 2013, 6(5):816-825.
64. Gupta P.K., Chullikana A., Parakh R., Desai S., Das A., Gottipamula S. A double blind randomized placebo controlled phase I/II study assessing the safety and efficacy of allogeneic bone marrow derived mesenchymal stem cell in critical limb ischemia. J Transl Med 2013, 11(1). 143.
65. Lee J.W., Lee S.H., Youn Y.J., Ahn M.S., Kim J.Y., Yoo B.S., et al. A randomized, open-label, multicenter trial for the safety and efficacy of adult mesenchymal stem cells after acute myocardial infarction. J Korean Med Sci 2014, 29(1):23-31.
66. Pak J., Chang J.J., Lee J.H., Lee S.H. Safety reporting on implantation of autologous adipose tissue-derived stem cells with platelet-rich plasma into human articular joints. BMC Musculoskelet Disord 2013, 14:337.
67. Le Blanc K., Tammik L., Sundberg B., Haynesworth S.E., Ringden O. Mesenchymal stem cells inhibit and stimulate mixed lymphocyte cultures and mitogenic responses independently of the major histocompatibility complex. Scand J Immunol 2003, 57(1):11-20.
68. Tse W.T., Pendleton J.D., Beyer W.M., Egalka M.C., Guinan E.C. Suppression of allogeneic T-cell proliferation by human marrow stromal cells: implications in transplantation. Transplantation 2003, 75(3):389-397.
69. Di Nicola M., Carlo-Stella C., Magni M., Milanesi M., Longoni P.D., Matteucci P., et al. Human bone marrow stromal cells suppress T-lymphocyte proliferation induced by cellular or nonspecific mitogenic stimuli. Blood 2002, 99(10):3838-3843.
70. Djouad F., Plence P., Bony C., Tropel P., Apparailly F., Sany J., et al. Immunosuppressive effect of mesenchymal stem cells favors tumor growth in allogeneic animals. Blood 2003, 102(10):3837-3844.
71. Potian J.A., Aviv H., Ponzio N.M., Harrison J.S., Rameshwar P. Veto-like activity of mesenchymal stem cells: functional discrimination between cellular responses to alloantigens and recall antigens. J Immunol 2003, 171(7):3426-3434.
72. Bartholomew A., Sturgeon C., Siatskas M., Ferrer K., McIntosh K., Patil S., et al. Mesenchymal stem cells suppress lymphocyte proliferation in vitro and prolong skin graft survival in vivo. Exp hematol 2002, 30(1):42-48.
73. Aggarwal S., Pittenger M.F. Human mesenchymal stem cells modulate allogeneic immune cell responses. Blood 2005, 105(4):1815-1822.
74. Maccario R., Podesta M., Moretta A., Cometa A., Comoli P., Montagna D., et al. Interaction of human mesenchymal stem cells with cells involved in alloantigen-specific immune response favors the differentiation of CD4+ T-cell subsets expressing a regulatory/suppressive phenotype. Haematologica 2005, 90(4):516-525.
75. Yan Z., Zhuansun Y., Chen R., Li J., Ran P. Immunomodulation of mesenchymal stromal cells on regulatory T cells and its possible mechanism. Exp Cell Res 2014, 324(1):65-74.
76. Krampera M., Glennie S., Dyson J., Scott D., Laylor R., Simpson E., et al. Bone marrow mesenchymal stem cells inhibit the response of naive and memory antigen-specific T cells to their cognate peptide. Blood 2003, 101(9):3722-3729.
77. Kim J.H., Lee Y.T., Hong J.M., Hwang Y.I. Suppression of in vitro murine T cell proliferation by human adipose tissue-derived mesenchymal stem cells is dependent mainly on cyclooxygenase-2 expression. Anat Cell biol 2013, 46(4):262-271.
78. Engela A.U., Hoogduijn M.J., Boer K., Litjens N.H., Betjes M.G., Weimar W., et al. Human adipose-tissue derived mesenchymal stem cells induce functional de-novo regulatory T cells with methylated FOXP3 gene DNA. Clin Exp Immunol 2013, 173(2):343-354.
79. Chen K., Wang D., Du W.T., Han Z.B., Ren H., Chi Y., et al. Human umbilical cord mesenchymal stem cells hUC-MSCs exert immunosuppressive activities through a PGE2-dependent mechanism. Clin Immunol 2010, 135(3):448-458.
80. Zhang W., Ge W., Li C., You S., Liao L., Han Q., et al. Effects of mesenchymal stem cells on differentiation, maturation, and function of human monocyte-derived dendritic cells. Stem Cells Dev 2004, 13(3):263-271.
81. Hegyi B., Kudlik G., Monostori E., Uher F. Activated T-cells and pro-inflammatory cytokines differentially regulate prostaglandin E2 secretion by mesenchymal stem cells. Biochem Biophys Res Commun 2012, 419(2):215-220.
82. Krampera M., Cosmi L., Angeli R., Pasini A., Liotta F., Andreini A., et al. Role for interferon-gamma in the immunomodulatory activity of human bone marrow mesenchymal stem cells. Stem Cells 2006, 24(2):386-398.
83. Ling W., Zhang J., Yuan Z., Ren G., Zhang L., Chen X., et al. Mesenchymal stem cells use IDO to regulate immunity in tumor microenvironment. Cancer Res 2014, 74(5):1576-1587.
84. Sotiropoulou P.A., Perez S.A., Gritzapis A.D., Baxevanis C.N., Papamichail M. Interactions between human mesenchymal stem cells and natural killer cells. Stem Cells 2006, 24(1):74-85.
85. Yen B.L., Yen M.L., Hsu P.J., Liu K.J., Wang C.J., Bai C.H., et al. Multipotent human mesenchymal stromal cells mediate expansion of myeloid-derived suppressor cells via hepatocyte growth factor/c-Met and STAT3. Stem Cell Rep 2013, 1(2):139-151.
86. Xu C.L., Yu P.F., Han X.Y., Du L.M., Gan J.H., Wang Y., et al. TGF-beta promotes immune responses in the presence of mesenchymal stem cells. J Immunol 2014, 192(1):103-109.
87. Rafei M., Campeau P.M., Aguilar-Mahecha A., Buchanan M., Williams P., Birman E., et al. Mesenchymal stromal cells ameliorate experimental autoimmune encephalomyelitis by inhibiting CD4 Th17 T cells in a CC chemokine ligand 2-dependent manner. J Immunol 2009, 182(10):5994-6002.
88. Shi Y., Hu G., Su J., Li W., Chen Q., Shou P., et al. Mesenchymal stem cells: a new strategy for immunosuppression and tissue repair. Cell Res 2010, 20(5):510-518.
89. Uccelli A., Pistoia V., Moretta L. Mesenchymal stem cells: a new strategy for immunosuppression?. Trends Immunol 2007, 28(5):219-226.
90. Zappia E., Casazza S., Pedemonte E., Benvenuto F., Bonanni I., Gerdoni E., et al. Mesenchymal stem cells ameliorate experimental autoimmune encephalomyelitis inducing T-cell anergy. Blood 2005, 106(5):1755-1761.
91. Schurch C.M., Riether C., Ochsenbein A.F. Cytotoxic CD8+ T cells stimulate hematopoietic progenitors by promoting cytokine release from bone marrow mesenchymal stromal cells. Cell Stem Cell 2014, 14(4):460-472.
92. Godfrey D.I., Stankovic S., Baxter A.G. Raising the NKT cell family. Nat Immunol 2010, 11(3):197-206.
93. Spaggiari G.M., Capobianco A., Becchetti S., Mingari M.C., Moretta L. Mesenchymal stem cell-natural killer cell interactions: evidence that activated NK cells are capable of killing MSCs, whereas MSCs can inhibit IL-2-induced NK-cell proliferation. Blood 2006, 107(4):1484-1490.
94. Selmani Z., Naji A., Zidi I., Favier B., Gaiffe E., Obert L., et al. Human leukocyte antigen-G5 secretion by human mesenchymal stem cells is required to suppress T lymphocyte and natural killer function and to induce CD4+CD25highFOXP3+ regulatory T cells. Stem Cells 2008, 26(1):212-222.
95. Prigione I., Benvenuto F., Bocca P., Battistini L., Uccelli A., Pistoia V. Reciprocal interactions between human mesenchymal stem cells and gammadelta T cells or invariant natural killer T cells. Stem Cells 2009, 27(3):693-702.
96. Corcione A., Benvenuto F., Ferretti E., Giunti D., Cappiello V., Cazzanti F., et al. Human mesenchymal stem cells modulate B-cell functions. Blood 2006, 107(1):367-372.
97. Uccelli A., Moretta L., Pistoia V. Mesenchymal stem cells in health and disease. Nat Rev Immunol 2008, 8(9):726-736.
98. Lee D.S., Yi T.G., Lee H.J., Kim S.N., Park S., Jeon M.S., et al. Mesenchymal stem cells infected with Mycoplasma arginini secrete complement C3 to regulate immunoglobulin production in b lymphocytes. Cell Death Dis 2014, 5. e1192.
99. Yan H., Wu M., Yuan Y., Wang Z.Z., Jiang H., Chen T. Priming of Toll-like receptor 4 pathway in mesenchymal stem cells increases expression of B cell activating factor. Biochem Biophys Res Commun 2014, 448(2):212-217.
100. Ungerer C., Quade-Lyssy P., Radeke H.H., Henschler R., Konigs C., Kohl U., et al. Galectin-9 is a suppressor of T and B cells and predicts the immune modulatory potential of mesenchymal stromal cell preparations. Stem Cells Dev 2014, 23(7):755-766.
101. Rosado M.M., Bernardo M.E., Scarsella M., Conforti A., Giorda E., Biagini S., et al. Inhibition of B-cell proliferation and antibody production by mesenchymal stromal cells is mediated by T cells. Stem Cells Dev 2014.
102. Ji Y.R., Yang Z.X., Han Z.B., Meng L., Liang L., Feng X.M., et al. Mesenchymal stem cells support proliferation and terminal differentiation of B cells. Cell Physiol Biochem 2012, 30(6):1526-1537.
103. Spaggiari G.M., Moretta L. Interactions between mesenchymal stem cells and dendritic cells. Adv Biochem Eng Biotechnol 2013, 130:199-208.
104. Nauta A.J., Kruisselbrink A.B., Lurvink E., Willemze R., Fibbe W.E. Mesenchymal stem cells inhibit generation and function of both CD34+-derived and monocyte-derived dendritic cells. J Immunol 2006, 177(4). 2080-7.
105. English K., Barry F.P., Mahon B.P. Murine mesenchymal stem cells suppress dendritic cell migration, maturation and antigen presentation. Immunol Lett 2008, 115(1):50-58.
106. Jiang X.X., Zhang Y., Liu B., Zhang S.X., Wu Y., Yu X.D., et al. Human mesenchymal stem cells inhibit differentiation and function of monocyte-derived dendritic cells. Blood 2005, 105(10):4120-4126.
107. Djouad F., Charbonnier L.M., Bouffi C., Louis-Plence P., Bony C., Apparailly F., et al. Mesenchymal stem cells inhibit the differentiation of dendritic cells through an interleukin-6-dependent mechanism. Stem Cells 2007, 25(8). 2025-32.
108. Spaggiari G.M., Abdelrazik H., Becchetti F., Moretta L. MSCs inhibit monocyte-derived DC maturation and function by selectively interfering with the generation of immature DCs: central role of MSC-derived prostaglandin E2. Blood 2009, 113(26):6576-6583.
109. Chiesa S., Morbelli S., Morando S., Massollo M., Marini C., Bertoni A., et al. Mesenchymal stem cells impair in vivo T-cell priming by dendritic cells. Proc Natl Acad Sci USA 2011, 108(42):17384-17389.
110. Raffaghello L., Bianchi G., Bertolotto M., Montecucco F., Busca A., Dallegri F., et al. Human mesenchymal stem cells inhibit neutrophil apoptosis: a model for neutrophil preservation in the bone marrow niche. Stem Cells 2008, 26(1):151-162.
111. Cassatella M.A., Mosna F., Micheletti A., Lisi V., Tamassia N., Cont C., et al. Toll-like receptor-3-activated human mesenchymal stromal cells significantly prolong the survival and function of neutrophils. Stem Cells 2011, 29(6):1001-1011.
112. Maqbool M., Vidyadaran S., George E., Ramasamy R. Human mesenchymal stem cells protect neutrophils from serum-deprived cell death. Cell Biol Int 2011, 35(12):1247-1251.
113. Nemeth K., Leelahavanichkul A., Yuen P.S., Mayer B., Parmelee A., Doi K., et al. Bone marrow stromal cells attenuate sepsis via prostaglandin E(2)-dependent reprogramming of host macrophages to increase their interleukin-10 production. Nat Med 2009, 15(1):42-49.
114. Cao X., Han Z.B., Zhao H., Liu Q. Transplantation of mesenchymal stem cells recruits trophic macrophages to induce pancreatic beta cell regeneration in diabetic mice. Int J Biochem Cell Biol 2014, 53:372-379.
115. Gao S., Mao F., Zhang B., Zhang L., Zhang X., Wang M., et al. Mouse bone marrow-derived mesenchymal stem cells induce macrophage M2 polarization through the nuclear factor-kappaB and signal transducer and activator of transcription 3 pathways. Exp Bio Med (Maywood) 2014, 239(3):366-375.
116. Abumaree M.H., Al Jumah M.A., Kalionis B., Jawdat D., Al Khaldi A., Abomaray F.M., et al. Human placental mesenchymal stem cells (pMSCs) play a role as immune suppressive cells by shifting macrophage differentiation from inflammatory M1 to anti-inflammatory M2 macrophages. Stem Cell Rev 2013, 9(5):620-641.
117. Cho D.I., Kim M.R., Jeong H.Y., Jeong H.C., Jeong M.H., Yoon S.H., et al. Mesenchymal stem cells reciprocally regulate the M1/M2 balance in mouse bone marrow-derived macrophages. Exp Mol Med 2014, 46. e70.
118. Oh J.Y., Lee R.H., Yu J.M., Ko J.H., Lee H.J., Ko A.Y., et al. Intravenous mesenchymal stem cells prevented rejection of allogeneic corneal transplants by aborting the early inflammatory response. Mol Ther 2012, 20(11):2143-2152.
119. Bassi E.J., Moraes-Vieira P.M., Moreira-Sa C.S., Almeida D.C., Vieira L.M., Cunha C.S., et al. Immune regulatory properties of allogeneic adipose-derived mesenchymal stem cells in the treatment of experimental autoimmune diabetes. Diabetes 2012, 61(10):2534-2545.
120. Anderson P., Souza-Moreira L., Morell M., Caro M., O'Valle F., Gonzalez-Rey E., et al. Adipose-derived mesenchymal stromal cells induce immunomodulatory macrophages which protect from experimental colitis and sepsis. Gut 2013, 62(8):1131-1141.
121. Mathias L.J., Khong S.M., Spyroglou L., Payne N.L., Siatskas C., Thorburn A.N., et al. Alveolar macrophages are critical for the inhibition of allergic asthma by mesenchymal stromal cells. J Immunol 2013, 191(12):5914-5924.
122. Lee M., Jeong S.Y., Ha J., Kim M., Jin H.J., Kwon S.J., et al. Low immunogenicity of allogeneic human umbilical cord blood-derived mesenchymal stem cells in vitro and in vivo. Biochem Biophys Res Commun 2014, 446(4):983-989.
123. Zanotti L., Sarukhan A., Dander E., Castor M., Cibella J., Soldani C., et al. Encapsulated mesenchymal stem cells for in vivo immunomodulation. Leukemia 2013, 27(2):500-503.
124. Gonzalez-Rey E., Anderson P., Gonzalez M.A., Rico L., Buscher D., Delgado M. Human adult stem cells derived from adipose tissue protect against experimental colitis and sepsis. Gut 2009, 58(7):929-939.
125. Hoogduijn M.J., Roemeling-van Rhijn M., Engela A.U., Korevaar S.S., Mensah F.K., Franquesa M., et al. Mesenchymal stem cells induce an inflammatory response after intravenous infusion. Stem Cells Dev 2013, 22(21):2825-2835.
126. Liu D., Xu J., Liu O., Fan Z., Liu Y., Wang F., et al. Mesenchymal stem cells derived from inflamed periodontal ligaments exhibit impaired immunomodulation. J Clin Periodontol 2012, 39(12):1174-1182.
127. Waterman R.S., Tomchuck S.L., Henkle S.L., Betancourt A.M. A new mesenchymal stem cell (MSC) paradigm: polarization into a pro-inflammatory MSC1 or an Immunosuppressive MSC2 phenotype. PloS One 2010, 5(4). e10088.
128. Liu L., Wang Y., Fan H., Zhao X., Liu D., Hu Y., et al. MicroRNA-181a regulates local immune balance by inhibiting proliferation and immunosuppressive properties of mesenchymal stem cells. Stem Cells 2012, 30(8):1756-1770.
129. Xu C., Ren G., Cao G., Chen Q., Shou P., Zheng C., et al. miR-155 regulates immune modulatory properties of mesenchymal stem cells by targeting TAK1-binding protein 2. J Biol Chem 2013, 288(16):11074-11079.
130. Ma J., Ning Y.N., Xu M., Hou Y., Wang N., Hou X.Y., et al. Thalidomide corrects impaired mesenchymal stem cell function in inducing tolerogenic DCs in patients with immune thrombocytopenia. Blood 2013, 122(12). 2074-82.
131. de Andrade A.V., Riewaldt J., Wehner R., Schmitz M., Odendahl M., Bornhauser M., et al. Gamma irradiation preserves immunosuppressive potential and inhibits clonogenic capacity of human bone marrow-derived mesenchymal stromal cells. J Cell Mol Med 2014, 18(6):1184-1193.
132. Zhuang Y., Li D., Fu J.Q., Shi Q., Lu Y.Y., Ju X.L. Comparison of biological properties of umbilical cord derived mesenchymal stem cells from early and late passages: immunomodulatory ability is enhanced in aged cells. Mol Med Rep 2014, 11(1):166-174.
133. Engela A.U., Baan C.C., Peeters A.M.A., Weimar W., Hoogdujin M.J. Interaction between adipose tissue-derived mesenchymal stem cells and regulatory T-cells. Cell Transplant 2013, 22(1):41-54.
134. Ferrara J.M.F., Levine J.E., Reddy P., Holler E. Graft-versus-host disease. Lancet 2009, 373(9674):1550-1561.
135. Baron F., Baker J.E., Storb R., Gooley T.A., Sandmaier B.M., Maris M.B., et al. Kinetics of engraftment in patients with hematologic malignancies given allogeneic hematopoietic cell transplantation after nonmyeloablative conditioning. Blood 2004, 104(8):2254-2262.
136. Tabbara I.A., Zimmerman K., Morgan C., Nahleh Z. Allogeneic hematopoietic stem cell transplantation: complications and results. Arch Intern Med 2002, 162(14):1558-1566.
137. Kim S.S. Treatment options in steroid-refractory acute graft-versus-host disease following hematopoietic stem cell transplantation. Ann Pharmacother 2007, 41(9):1436-1444.
138. Le Blanc K., Rasmusson I., Sundberg B., Gotherstrom C., Hassan M., Uzunel M., et al. Treatment of severe acute graft-versus-host disease with third party haploidentical mesenchymal stem cells. Lancet 2004, 363(9419):1439-1441.
139. Le Blanc K., Samuelsson H., Gustafsson B., Remberger M., Sundberg B., Arvidson J., et al. Transplantation of mesenchymal stem cells to enhance engraftment of hematopoietic stem cells. Leukemia 2007, 21(8):1733-1738.
140. Ringden O., Uzunel M., Rasmusson I., Remberger M., Sundberg B., Lonnies H., et al. Mesenchymal stem cells for treatment of therapy-resistant graft-versus-host disease. Transplantation 2006, 81(10):1390-1397.
141. Herrmann RP, Sturm MJ. Adult human mesenchymal stromal cells and the treatment of graft versus host disease. Stem Cells Cloning; 7: 45-52.
142. Ball L.M., Bernardo M.E., Roelofs H., van Tol M.J., Contoli B., Zwaginga J.J., et al. Multiple infusions of mesenchymal stromal cells induce sustained remission in children with steroid-refractory, grade III-IV acute graft-versus-host disease. Br J Haematol 2013, 163(4):501-509.
143. Muroi K., Miyamura K., Ohashi K., Murata M., Eto T., Kobayashi N., et al. Unrelated allogeneic bone marrow-derived mesenchymal stem cells for steroid-refractory acute graft-versus-host disease: a phase I/II study. Int J Hematol 2013, 98(2):206-213.
144. Ringden O., Erkers T., Nava S., Uzunel M., Iwarsson E., Conrad R., et al. Fetal membrane cells for treatment of steroid-refractory acute graft-versus-host disease. Stem Cells 2013, 31(3):592-601.
145. Lazarus H.M., Haynesworth S.E., Gerson S.L., Rosenthal N.S., Caplan A.I. Ex vivo expansion and subsequent infusion of human bone marrow-derived stromal progenitor cells (mesenchymal progenitor cells): implications for therapeutic use. Bone Marrow Transplant 1995, 16(4):557-564.
146. Lazarus H.M., Koc O.N., Devine S.M., Curtin P., Maziarz R.T., Holland H.K., et al. Cotransplantation of HLA-identical sibling culture-expanded mesenchymal stem cells and hematopoietic stem cells in hematologic malignancy patients. Biol Blood Marrow Transplant 2005, 11(5):389-398.
147. Kuzmina L.A., Petinati N.A., Parovichnikova E.N., Lubimova L.S., Gribanova E.O., Gaponova T.V., et al. Multipotent Mesenchymal Stromal Cells for the Prophylaxis of Acute Graft-versus-Host Disease-A Phase II Study. Stem Cells Int 2012 2012, 968213.
148. Manochantr S., Y U.P., Kheolamai P., Rojphisan S., Chayosumrit M., Tantrawatpan C., et al. Immunosuppressive properties of mesenchymal stromal cells derived from amnion, placenta, Wharton's jelly and umbilical cord. Intern Med J 2013, 43(4):430-439.
149. Wu Y., Wang Z., Cao Y., Xu L., Li X., Liu P., et al. Cotransplantation of haploidentical hematopoietic and umbilical cord mesenchymal stem cells with a myeloablative regimen for refractory/relapsed hematologic malignancy. Ann Hematol 2013, 92(12):1675-1684.
150. Li X.H., Gao C.J., Da W.M., Cao Y.B., Wang Z.H., Xu L.X., et al. Reduced intensity conditioning, combined transplantation of haploidentical hematopoietic stem cells and mesenchymal stem cells in patients with severe aplastic anemia. PLoS One 2014, (3):9. e89666.
151. Wu Y., Cao Y., Li X., Xu L., Wang Z., Liu P., et al. Cotransplantation of haploidentical hematopoietic and umbilical cord mesenchymal stem cells for severe aplastic anemia: successful engraftment and mild GVHD. Stem Cell Res 2014, 12(1):132-138.
152. Li J.P., Zheng C.L., Han Z.C. Abnormal immunity and stem/progenitor cells in acquired aplastic anemia. Crit Rev Oncol Hematol 2010, 75(2):79-93.
153. Chen X., Armstrong M.A., Li G. Mesenchymal stem cells in immunoregulation. Immunol Cell Biol 2006, 84(5):413-421.
154. Guo Z., Zheng C., Chen Z., Gu D., Du W., Ge J., et al. Fetal BM-derived mesenchymal stem cells promote the expansion of human Th17 cells, but inhibit the production of Th1 cells. Eur J Immunol 2009, 39(10):2840-2849.
155. Bacigalupo A., Valle M., Podesta M., Pitto A., Zocchi E., De Flora A., et al. T-cell suppression mediated by mesenchymal stem cells is deficient in patients with severe aplastic anemia. Exp Hematol 2005, 33(7):819-827.
156. Chao Y.H., Peng C.T., Harn H.J., Chan C.K., Wu K.H. Poor potential of proliferation and differentiation in bone marrow mesenchymal stem cells derived from children with severe aplastic anemia. Ann Hematol 2010, 89(7):715-723.
157. Li J., Lu S., Yang S., Xing W., Feng J., Li W., et al. Impaired immunomodulatory ability of bone marrow mesenchymal stem cells on CD4 (+) T cells in aplastic anemia. Results Immunol 2012, 2:142-147.
158. Li J., Yang S., Lu S., Zhao H., Feng J., Li W., et al. Differential gene expression profile associated with the abnormality of bone marrow mesenchymal stem cells in aplastic anemia. PLoS One 2012, 7(11). e47764.
159. Xiao Y., Jiang Z.J., Pang Y., Li L., Gao Y., Xiao H.W., et al. Efficacy and safety of mesenchymal stromal cell treatment from related donors for patients with refractory aplastic anemia. Cytotherapy 2013, 15(7):760-766.
160. Ozdogu H., Yeral M., Boga C., Kozanoglu I. Use of mesenchymal cells to modulate immune suppression and immune reconstruction in a patient with aplastic anemia complicated by invasive sino-orbital aspergillosis. Turk J Haematol 2014, 31(2):181-183.
161. Fang B., Li N., Song Y., Li J., Zhao R.C., Ma Y. Cotransplantation of haploidentical mesenchymal stem cells to enhance engraftment of hematopoietic stem cells and to reduce the risk of graft failure in two children with severe aplastic anemia. Pediatr Transplant 2009, 13(4):499-502.
162. Wang H., Wang Z., Xue M., Liu J., Yan H., Guo Z. Co-transfusion of haplo-identical hematopoietic and mesenchymal stromal cells to treat a patient with severe aplastic. Cytotherapy 2012, 12(4):563-565.
163. Keegan B.M., Noseworthy J.H. Multiple sclerosis. Ann Rev Med 2002, 53:285-302.
164. de Oliveira G.L., de Lima K.W., Colombini A.M., Pinheiro D.G., Panepucci R.A., Palma P.V., et al. Bone marrow mesenchymal stromal cells isolated from multiple sclerosis patients have distinct gene expression profile and decreased suppressive function compared with healthy counterparts. Cell Transplant 2013.
165. Connick P., Kolappan M., Crawley C., Webber D.J., Patani R., Michell A.W., et al. Autologous mesenchymal stem cells for the treatment of secondary progressive multiple sclerosis: an open-label phase 2a proof-of-concept study. Lancet Neurol 2012, 11(2):150-156.
166. Mohajeri M., Farazmand A. Mohyeddin Bonab M, Nikbin B, Minagar A. FOXP3 gene expression in multiple sclerosis patients pre- and post mesenchymal stem cell therapy. Iran J Allergy Asthma Immunol 2011, 10(3):155-161.
167. Hou Z.L., Liu Y., Mao X.H., Wei C.Y., Meng M.Y., Liu Y.H., et al. Transplantation of umbilical cord and bone marrow-derived mesenchymal stem cells in a patient with relapsing-remitting multiple sclerosis. Cell Adhes Migrat 2013, 7(5):404-407.
168. Liang J., Li X., Zhang H., Wang D., Feng X., Wang H., et al. Allogeneic mesenchymal stem cells transplantation in patients with refractory RA. Clin Rheumatol 2012, 31(1):157-161.
169. Duijvestein M., Vos A.C., Roelofs H., Wildenberg M.E., Wendrich B.B., Verspaget H.W., et al. Autologous bone marrow-derived mesenchymal stromal cell treatment for refractory luminal Crohn's disease: results of a phase I study. Gut 2010, 59(12):1662-1669.
170. Ciccocioppo R., Bernardo M.E., Sgarella A., Maccario R., Avanzini M.A., Ubezio C., et al. Autologous bone marrow-derived mesenchymal stromal cells in the treatment of fistulising Crohn's disease. Gut 2011, 60(6):788-798.
171. Cho Y.B., Lee W.Y., Park K.J., Kim M., Yoo H.W., Yu C.S. Autologous adipose tissue-derived stem cells for the treatment of Crohn's fistula: a phase I clinical study. Cell Transplant 2013, 22(2):279-285.
172. de la Portilla F., Alba F., Garcia-Olmo D., Herrerias J.M., Gonzalez F.X., Galindo A. Expanded allogeneic adipose-derived stem cells (eASCs) for the treatment of complex perianal fistula in Crohn's disease: results from a multicenter phase I/IIa clinical trial. Int J Colorectal Dis 2013, 28(3):313-323.
173. Forbes G.M., Sturm M.J., Leong R.W., Sparrow M.P., Segarajasingam D., Cummins A.G., et al. A phase 2 study of allogeneic mesenchymal stromal cells for luminal Crohn's disease refractory to biologic therapy. Clin Gastroenterol Hepatol 2014, 12(1):64-71.
174. Hoffman R.W. T cells in the pathogenesis of systemic lupus erythematosus. Clin Immunol 2004, 113(1):4-13.
175. Sanz I. Connective tissue diseases: targeting B cells in SLE: good news at last!. Nat Rev Rheumatol 2011, 7(5):255-256.
176. Bernatsky S., Boivin J.F., Joseph L., Manzi S., Ginzler E., Gladman D.D., et al. Mortality in systemic lupus erythematosus. Arthritis Rheum 2006, 54(8):2550-2557.
177. Tang Y., Ma X., Zhang H., Gu Z., Hou Y., Gilkeson G.S., et al. Gene expression profile reveals abnormalities of multiple signaling pathways in mesenchymal stem cell derived from patients with systemic lupus erythematosus. Clin Dev Immunol 2012, 2012:826182.
178. Tang Y., Xie H., Chen J., Geng L., Chen H., Li X., et al. Activated NF-kappaB in bone marrow mesenchymal stem cells from systemic lupus erythematosus patients inhibits osteogenic differentiation through downregulating Smad signaling. Stem Cells Dev 2013, 22(4):668-678.
179. Gu Z., Cao X., Jiang J., Li L., Da Z., Liu H., et al. Upregulation of p16INK4A promotes cellular senescence of bone marrow-derived mesenchymal stem cells from systemic lupus erythematosus patients. Cell Signal 2012, 24(12):2307-2314.
180. Gu Z., Jiang J., Tan W., Xia Y., Cao H., Meng Y., et al. p53/p21 Pathway involved in mediating cellular senescence of bone marrow-derived mesenchymal stem cells from systemic lupus erythematosus patients. Clin Dev Immunol 2013, 2013:134243.
181. Gu Z., Tan W., Feng G., Meng Y., Shen B., Liu H., et al. Wnt/beta-catenin signaling mediates the senescence of bone marrow-mesenchymal stem cells from systemic lupus erythematosus patients through the p53/p21 pathway. Mol Cell Biochem 2014, 387(1-2):27-37.
182. Nie Y., Lau C., Lie A., Chan G., Mok M. Defective phenotype of mesenchymal stem cells in patients with systemic lupus erythematosus. Lupus 2010, 19(7):850-859.
183. Alexander T., Thiel A., Rosen O., Massenkeil G., Sattler A., Kohler S., et al. Depletion of autoreactive immunologic memory followed by autologous hematopoietic stem cell transplantation in patients with refractory SLE induces long-term remission through de novo generation of a juvenile and tolerant immune system. Blood 2009, 113(1):214-223.
184. Li X., Wang D., Liang J., Zhang H., Sun L. Mesenchymal SCT ameliorates refractory cytopenia in patients with systemic lupus erythematosus. Bone marrow Transplant 2013, 48(4):544-550.
185. Wang D., Zhang H., Liang J., Li X., Feng X., Wang H., et al. Allogeneic mesenchymal stem cell transplantation in severe and refractory systemic lupus erythematosus: 4 years of experience. Cell Transplant 2013, 22(12):2267-2277.
186. Wang D., Li J., Zhang Y., Zhang M., Chen J., Li X., et al. Umbilical cord mesenchymal stem cell transplantation in active and refractory systemic lupus erythematosus: a multicenter clinical study. Arthritis Res Ther 2014, 16(2). R79.
187. Bernardo M.E., Fibbe W.E. Mesenchymal stromal cells: sensors and switchers of inflammation. Cell Stem Cell 2013, 13(4):392-402.
188. Skrahin A., Ahmed R.K., Ferrara G., Rane L., Poiret T., Isaikina Y., et al. Autologous mesenchymal stromal cell infusion as adjunct treatment in patients with multidrug and extensively drug-resistant tuberculosis: an open-label phase 1 safety trial. Lancet Respir Med 2014, 2(2):108-122.
189. Liu R., Zhang Z., Lu Z., Borlongan C., Pan J., Chen J., et al. Human umbilical cord stem cells ameliorate experimental autoimmune encephalomyelitis by regulating immunoinflammation and remyelination. Stem Cells Dev 2013, 22(7):1053-1062.
190. Zhang Z., Fu J., Xu X., Wang S., Xu R., Zhao M., et al. Safety and immunological responses to human mesenchymal stem cell therapy in difficult-to-treat HIV-1-infected patients. AIDS 2013, 27(8):1283-1293.